Synergistic Anticancer Activity of Topotecan— Cyclin-Dependent Kinase Inhibitor Combinations against Drug-Resistant Small Cell Lung Cancer (SCLC) Cell Lines

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.net/journal/jct
E-mail: [email protected]

Citations

"Synergistic Anticancer Activity of Topotecan— Cyclin-Dependent Kinase Inhibitor Combinations against Drug-Resistant Small Cell Lung Cancer (SCLC) Cell Lines"
written by Gerhard Hamilton, Ulrike Olszewski, Lukas Klameth, Ernst Ulsperger, Klaus Geissler,
published by Journal of Cancer Therapy, Vol.4 No.8A, 2013

has been cited by the following article(s):

[1]	Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
	Marine Drugs, 2018

[2]	Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy
	Cancer letters, 2015

[3]	Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines
	Marine drugs, 2014

[4]	Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
	Molecules, 2014

[1]	Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines Marine Drugs, 2018 DOI:10.3390/md16100383

[2]	Next Generation Sequencing in Cancer Research, Volume 2 2015 DOI:10.1007/978-3-319-15811-2_7

[3]	Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy Cancer Letters, 2015 DOI:10.1016/j.canlet.2014.09.025

[4]	Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines Marine Drugs, 2014 DOI:10.3390/md12031377

[5]	Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines Molecules, 2014 DOI:10.3390/molecules19022077